Araceli Biosciences, a pioneering biotechnology company revolutionizing high-content imaging and AI-powered analytics, announced the successful closing of its seed funding round. It raised $7.2 million in new equity investments and converted $4.0 million into SAFEs, bringing the total funding raised since Araceli’s spin-off from Phoseon Technology to $11.2 million. This funding will accelerate Araceli’s commercial expansion, scale manufacturing, and advance its next-generation AI-driven product offering in high-content imaging.
Overcoming the Imaging Bottleneck in Drug Discovery
The Endeavor® High Content Imaging System is Araceli’s flagship platform, engineered for ultra-high-throughput imaging with exceptional data quality, delivering results up to 40 times faster than conventional systems across a wide range of cellular assays. Combined with Clairvoyance, Araceli’s AI-powered analytics software, the platform delivers rapid, actionable insights that streamline workflows, reduce experimental errors, and significantly accelerate time to drug discovery.
While advances in automation, genomics, and machine learning have transformed drug discovery, high-resolution imaging remains one of the slowest steps and a major bottleneck. Conventional imaging systems lack the speed and scalability required for modern AI-driven pipelines and multiplexed assays. Araceli addresses this critical gap with a platform purpose-built for speed, scalability, and seamless AI integration, enabling researchers to generate more data faster and with greater accuracy.
Also Read: Axtria Launches Agentic AI to Boost Life Sciences Growth
Strategic use of funds
The proceeds from the seed capital round will be used for the following purposes:
- Scaling operational infrastructure to meet growing demand
- Advancing market applications, including personalized medicine
- Further development of the platform’s hardware and software for real-time analytics capabilities
- Expanding marketing and business development efforts
“The future of AI-powered drug development and personalized medicine depends on real-time imaging and analytics,” explained Matt Beaudet , CEO of Araceli Biosciences. “Minutes and seconds are critical. The old model of waiting hours or even days for data is outdated. At Araceli, we are developing a platform that keeps pace with the speed of science.”
Bill Cortelyou , Board Chair and lead investor, added: “Thanks to its groundbreaking technology, experienced leadership and clear market demand, the company has significant growth potential.”
Source: PRNewswire
